Advantage Investment Management’s PDS Biotechnology PDSB Stock Holding History

Advantage Investment Management’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$0	Hold	45	–	–	﹤0.01%	952
2019 Q2	$0	Hold	45	–	–	﹤0.01%	954
2019 Q1	$0	Hold	45	–	–	﹤0.01%	988
2018 Q4	$0	Hold	45	–	–	﹤0.01%	1052
2018 Q3	$1K	Hold	45	–	–	﹤0.01%	982
2018 Q2	$1K	Hold	45	–	–	﹤0.01%	915
2018 Q1	$1K	Hold	45	–	–	﹤0.01%	966
2017 Q4	$8K	Hold	45	–	–	﹤0.01%	737
2017 Q3	$10K	Hold	45	–	–	﹤0.01%	692
2017 Q2	$9K	Hold	45	–	–	﹤0.01%	727
2017 Q1	$8K	Buy	45 +20	+80%	+$3.96K	﹤0.01%	730
2016 Q4	$6K	Hold	25	–	–	﹤0.01%	724
2016 Q3	$5K	Hold	25	–	–	﹤0.01%	738
2016 Q2	$5K	Hold	25	–	–	﹤0.01%	709
2016 Q1	$5K	Buy	+25	New	+$4.47K	﹤0.01%	682

Other funds holding PDSB

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

RegentAtlantic Capital Morristown, New Jersey $3.34B AUM 14.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IGGA

Iron Gate Global Advisors Nsl, Utah $947M AUM 23.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Advantage Investment Management's PDSB Position: Q3 2019 in Review

Advantage Investment Management held its PDS Biotechnology (PDSB) position steady in Q3 2019 at 45 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #952.

Advantage Investment Management first reported a position in PDSB in Q1 2016 and has held it in 15 quarters since. The position peaked at $10K in Q3 2017. 21 funds tracked by Wall St. Rank hold PDSB as of Q3 2019.

Advantage Investment Management held 45 shares of PDS Biotechnology worth $0 as of Q3 2019.
Advantage Investment Management left its PDS Biotechnology share count unchanged in Q3 2019.
PDS Biotechnology made up ﹤0.01% of Advantage Investment Management's portfolio in Q3 2019, its #952 holding.
Advantage Investment Management first reported a position in PDS Biotechnology in Q1 2016 and has held it in 15 quarters since.
Advantage Investment Management's PDS Biotechnology position peaked at $10K in Q3 2017.
21 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.